These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7611841)

  • 1. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
    Gust R; Karl J; Faderl M; Schönenberger H
    Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
    Karl J; Gust R; Spruss T; Schneider MR; Schönenberger H; Engel J; Wrobel KH; Lux F; Haeberlin ST
    J Med Chem; 1988 Jan; 31(1):72-83. PubMed ID: 3336035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2001 Oct; 334(10):309-17. PubMed ID: 11759169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the conformational influences on the estrogenic activity of 1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their platinum(II) complexes, II: Synthesis and studies on the estrogenic activity of cis- and trans[bis(2,6-dichloro-4-hydroxybenzylamine)]dihaloplatinum(II)-c omplexes.
    Gust R; Schönenberger H
    Arch Pharm (Weinheim); 1994 Dec; 327(12):763-9. PubMed ID: 7872853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
    Gust R; Niebler K; Schönenberger H
    J Med Chem; 2005 Nov; 48(23):7132-44. PubMed ID: 16279771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical stability, biological activity and cellular uptake of a cisplatin analogue having a 1,2-diarylethyleneamine ligand in cultures of human breast cancer cells.
    Otto AM; Kratochwil NA; Eggers H; Bednarski PJ
    J Cancer Res Clin Oncol; 1995; 121(1):31-8. PubMed ID: 7860616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure activity studies on leaving group derivatives of [meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] platinum(II).
    Gust R; Keilitz R; Krauser R; Schmidt K; Schnurr B
    Arch Pharm (Weinheim); 1999 Aug; 332(8):261-70. PubMed ID: 10489536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammary tumor inhibiting [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, III: Relationship between structure and estrogenic activity of the diamine ligands, their sulfatoplatinum(II) and diiodoplatinum(II) complexes.
    Gust R; Schönenberger H
    Arch Pharm (Weinheim); 1993 Jul; 326(7):405-13. PubMed ID: 8357303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.
    Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
    Arch Pharm (Weinheim); 1989 Feb; 322(2):67-73. PubMed ID: 2730292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: Synthesis.
    Müller R; Schickaneder E; Jennerwein M; Reile H; Spruss T; Engel J; Schönenberger H
    Arch Pharm (Weinheim); 1991 Feb; 324(2):115-20. PubMed ID: 1854235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part II. Studies on the influence of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) on the specific immune defense in MXT-M-3,2 breast cancer bearing mice.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2000 Dec; 333(12):397-403. PubMed ID: 11199469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic properties.
    Schertl S; Hartmann RW; Batzl-Hartmann C; Schlemmer R; Spruss T; Bernhardt G; Gust R; Schönenberger H
    Arch Pharm (Weinheim); 2001 Apr; 334(4):125-37. PubMed ID: 11382148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
    von Angerer E; Birnböck H; Knebel N
    Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer.
    Müller R; Gust R; Bernhardt G; Keller C; Schönenberger H; Seeber S; Osieka R; Eastman A; Jennerwein M
    J Cancer Res Clin Oncol; 1990; 116(3):237-44. PubMed ID: 2370248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
    Gust R; Faderl M; Schönenberger H
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis.
    Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
    Arch Pharm (Weinheim); 1989 Jan; 322(1):25-9. PubMed ID: 2730286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2- phenylethylenediamine]sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring, II: Correlation of molecular structure and estrogenic activity of breast and prostate cancer inhibiting. [erythro-1-(2,6-dichloro-4-hydroxyphenyl)-2-(2-halo-4- hydroxyphenyl)ethylenediamine]platinum(II) complexes.
    Gust R; Schönenberger H; Klement U; Range KJ
    Arch Pharm (Weinheim); 1993 Dec; 326(12):967-76. PubMed ID: 8122966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2000 Mar; 333(2-3):69-71. PubMed ID: 10783521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aqua[1,1-bis(4-hydroxyphenyl)-1,2-diamino-2-phenylethane]- sulfatoplatinum(II), a new compound for the treatment of the mammary carcinoma.
    Gust R
    Arch Pharm (Weinheim); 1994 Jan; 327(1):49-54. PubMed ID: 8117188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.